# Test Results: writing/methods-drafting.md

> ⚠️  Raw model output captured automatically by the cross-model test harness on 2026-06-23.
> This output is **not yet verified**. An author must read the output and set the
> assessment below before this counts as a tested result (see CLAUDE.md, Hard Rules).

## Test Metadata
- **Prompt:** writing/methods-drafting.md
- **Model:** claude-sonnet-4.6
- **Model ID (pinned):** claude-sonnet-4-6
- **Endpoint:** native
- **Date:** 2026-06-23
- **Tester:** cross-model-harness
- **Assembly strategy:** concat
- **Temperature:** 0.0

## Test Input Used
Standard test input from prompt file (`## Test Input`).

## Filled Prompt
```
Context: I am preparing a Methods section for a manuscript on {RESEARCH_TOPIC} targeting {JOURNAL_TYPE: e.g., "a microbiology journal," "a broad-audience journal like Nature Communications"}. Below are my detailed notes on the methods I used.

My notes:
{DETAILED_NOTES}

Task: Draft a Methods section based on my notes. Structure the section with the following subsections:

1. {SUBSECTION_1: e.g., "Study Design and Sample Collection"}
2. {SUBSECTION_2: e.g., "DNA Extraction and Sequencing"}
3. {SUBSECTION_3: e.g., "Bioinformatic Analysis"}
4. {SUBSECTION_4: e.g., "Statistical Analysis"}
[Adjust subsections to match your study]

For each subsection:
- Write in past tense, passive or active voice as appropriate for the target journal
- Include specific details: reagent names, concentrations, instrument settings, software versions
- State the purpose of each step where not obvious
- Note sample sizes and replicates

Constraints:
- Use ONLY information from my notes—do not add steps, reagents, or parameters I didn't specify
- If my notes are missing critical details, flag them as [MISSING: description] rather than inventing values
- Do not add interpretation or results—this is Methods only
- Keep prose clear and direct; avoid unnecessary hedging

Output format: Structured prose with subsection headers. Flag any gaps or ambiguities for my attention.

Context: I am preparing a Methods section for a manuscript on fecal microbiota transplantation efficacy targeting a clinical microbiology journal. Below are my detailed notes.

My notes:

Study design:
- Randomized, double-blind, placebo-controlled trial
- Patients with recurrent C. difficile infection (≥3 episodes)
- Enrolled at two academic medical centers

Participants:
- n=48 patients randomized (24 FMT, 24 placebo)
- Age 18-75, both sexes
- Exclusion: immunocompromised, pregnant, IBD

FMT preparation:
- Single healthy donor, screened per FDA guidelines
- Fresh stool processed within 6 hours
- Mixed with saline, filtered, 50mL final volume

Intervention:
- FMT or placebo via colonoscopy
- Placebo was saline with food coloring to match appearance
- Patients blinded to allocation

Outcomes:
- Primary: CDI recurrence within 8 weeks
- Secondary: microbiome diversity at weeks 1, 4, 8

Sample collection:
- Stool samples at baseline, week 1, 4, 8
- Stored -80C within 2 hours

Microbiome analysis:
- DNA extraction: MoBio PowerFecal kit
- 16S V4 region, 515F/806R primers
- Illumina MiSeq 2x250bp
- QIIME2 with DADA2 for ASV inference

Subsections needed:
1. Study Design and Participants
2. FMT Preparation and Administration
3. Outcome Measures
4. Microbiome Analysis
5. Statistical Analysis [notes missing for this]
```

## Model Output
```
# Methods

## Study Design and Participants

This randomized, double-blind, placebo-controlled trial was conducted at two academic medical centers. Adults aged 18–75 years with recurrent *Clostridioides difficile* infection (CDI), defined as three or more episodes, were eligible for enrollment. Patients were excluded if they were immunocompromised, pregnant, or had a diagnosis of inflammatory bowel disease. A total of 48 patients were randomized in a 1:1 ratio to receive either fecal microbiota transplantation (FMT; n = 24) or placebo (n = 24). Allocation concealment and blinding procedures are described below. [MISSING: Specify the randomization method used, e.g., block randomization, stratified by site or age, and who generated the allocation sequence. Also clarify whether patients, clinicians, and outcome assessors were all blinded, or only patients.]

---

## FMT Preparation and Administration

Donor stool was obtained from a single healthy donor screened in accordance with current FDA guidelines. [MISSING: Specify which FDA guidance document or screening panel was followed, e.g., FDA 2023 guidance on IND requirements for FMT, and list the pathogen screening tests performed if applicable.] Fresh stool was processed within 6 hours of collection. The material was mixed with sterile saline, filtered to remove particulate matter [MISSING: specify filter pore size or filtration method], and prepared as a 50 mL suspension for administration.

FMT or placebo was delivered via colonoscopy. The placebo consisted of sterile saline with food coloring added to match the macroscopic appearance of the FMT preparation, thereby maintaining patient blinding. [MISSING: Specify the anatomical site of infusion, e.g., cecum or terminal ileum, and whether any bowel preparation was required prior to colonoscopy.] Patients were blinded to treatment allocation throughout the study period.

---

## Outcome Measures

The primary outcome was CDI recurrence within 8 weeks of the intervention, defined as [MISSING: provide the clinical or laboratory definition of recurrence used, e.g., ≥3 unformed stools per day with a positive *C. difficile* toxin assay]. Secondary outcomes included fecal microbiome diversity assessed at weeks 1, 4, and 8 post-intervention.

Stool samples for microbiome analysis were collected from all participants at baseline and at weeks 1, 4, and 8. Samples were stored at −80°C within 2 hours of collection.

---

## Microbiome Analysis

Genomic DNA was extracted from fecal samples using the MoBio PowerFecal Kit according to the manufacturer's instructions. [MISSING: Specify whether any bead-beating or additional homogenization steps were used, and whether DNA yield or quality was assessed prior to sequencing.] The V4 hypervariable region of the 16S rRNA gene was amplified using the 515F/806R primer pair. [MISSING: Provide PCR cycling conditions, including number of cycles, annealing temperature, and polymerase used. Also specify whether samples were amplified in duplicate or triplicate.] Amplicon libraries were sequenced on the Illumina MiSeq platform using 2×250 bp paired-end chemistry. [MISSING: State the target sequencing depth per sample.]

Bioinformatic processing was performed in QIIME2 [MISSING: specify version, e.g., QIIME2 2023.5]. Paired-end reads were denoised and amplicon sequence variants (ASVs) were inferred using the DADA2 plugin. [MISSING: Specify DADA2 truncation lengths, quality filtering thresholds, and chimera removal settings applied. Also specify the reference database used for taxonomic classification, e.g., SILVA 138 or Greengenes2, and the classifier type.] Alpha diversity metrics [MISSING: specify which metrics, e.g., Shannon index, observed ASVs, Faith's phylogenetic diversity] and beta diversity metrics [MISSING: specify which metrics, e.g., Bray–Curtis dissimilarity, UniFrac] were calculated to assess within-sample and between-sample diversity, respectively, at each time point.

---

## Statistical Analysis

> ⚠️ **FLAG — Section Missing:** No statistical analysis notes were provided. This subsection requires the following information before it can be drafted:
>
> - **Primary outcome analysis:** Test used to compare CDI recurrence rates between groups (e.g., Fisher's exact test, chi-square, or log-rank test if time-to-event analysis was used)
> - **Sample size and power calculation:** The basis for enrolling 48 patients (assumed recurrence rates, alpha, power)
> - **Microbiome diversity comparisons:** Tests used for alpha diversity (e.g., Mann–Whitney U, linear mixed-effects models) and beta diversity (e.g., PERMANOVA)
> - **Handling of multiple time points:** Whether a repeated-measures framework was applied
> - **Missing data:** How dropouts or missing samples were handled (e.g., intention-to-treat vs. per-protocol analysis)
> - **Software:** Statistical software and version used (e.g., R 4.3.1, SAS 9.4)
> - **Significance threshold:** Alpha level used (e.g., p < 0.05)

---

### Summary of Flags for Author Review

| Location | Issue |
|---|---|
| Study Design | Randomization method and blinding scope not specified |
| FMT Preparation | FDA screening protocol and filtration method not specified |
| FMT Administration | Infusion site and bowel preparation not specified |
| Outcome Measures | Clinical/laboratory definition of CDI recurrence not specified |
| Microbiome Analysis | PCR conditions, sequencing depth, QIIME2 version, DADA2 parameters, and reference database not specified |
| Microbiome Analysis | Specific diversity metrics not specified |
| Statistical Analysis | Entire subsection missing — see detailed flag above |
```

## Assessment
_To be completed by a human reviewer. Do not mark Pass without reading the output._

### Task Achievement
- **Achieved:** [Yes / No / Partial]
- **Notes:**

### Constraint Compliance
- **All constraints respected:** [Yes / No]
- **Violations noted:**

### Failure Modes
- **Failure modes observed:** [None / list]
- **Mitigation effectiveness:**

### Output Format
- **Format correct:** [Yes / No]
- **Deviations:**

## Overall Assessment
- **Recommendation:** PENDING AUTHOR REVIEW
- **Notes:**

## Verification Steps Tested
_Which verification requirements from the prompt were checked, and results._
